RenalGuard System for Prevention of Contrast Induced Nephropathy

RenalGuard System for Prevention of Contrast Induced Nephropathy - A Randomized Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02029820

Acronym

REPRECIN

Enrollment

210

Registered

2014-01-08

Start date

2012-08-31

Completion date

2015-12-31

Last updated

2014-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiographic Contrast Agent Nephropathy

Keywords

Contrast Nephropathy, Prevention, Renalguard

Brief summary

The purpose of this study is to determine whether hydration with intravenous saline matched with urine output, using the device RenalGuard is superior to standard hydration with saline to prevent contrast-induced nephropathy.

Interventions

DEVICERenalGuard

Intravenous saline hydration matched with urine output, using the device Renalguard

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* serum creatinine \>1.2mg/dl * glomerular filtration rate (GFR) \< 60ml/min

Exclusion criteria

* acute renal failure * use of radiological contrast in the latest 7 days * Current use of N-acetylcysteine or hydration of sodium bicarbonate * Patients in dialysis * Emergency procedures

Design outcomes

Primary

Measure	Time frame	Description
Incidence of contrast-induced nephropathy	72 hours	Contrast-induced nephropathy defined as an increase of serum creatinine of 0.5mg/dl or 25% in pre procedure serum creatinine at 72h after procedure

Countries

Brazil

Contacts

Primary ContactAryadina Piva, RN

pesquisa@cardiarte.com.br55 51 33203494

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026